The most common diagnosis was equally Autosomal Dominant Polycystic Kidney Disease (21.7%) and Medullary Cystic Kidney Disease (21.7%) followed by Alport Syndrome (10.1%). 45 patients (63.4%) exhibited an additional extra-renal phenotype, 12 of whom (17%) required referral to other clinical services from this clinic. 52.1% of patients had a genetic
test requested after an informed consent process. Conclusions: The multidisciplinary team clinic model described and implemented has been subjectively beneficial with regard to provision of subspecialty assessment, diagnostics, disease information, genetic counselling, identification of at risk individuals and appropriate management where applicable. Our positive experience suggests consideration should be given for individualisation and application High Content Screening Everolimus manufacturer in other Australian locations. 213 MEAL REPLACEMENTS FOR OBESITY MANAGEMENT IN CKD J MURRAY1, V LOK3, S NOBLE3, J MURRAY4, S VENNING1, I HILLSTEAD5, A LEE6, K CAMPBELL1,2 1Department of Nutrition and Dietetics and Nephrology; 2Princess Alexandra Hospital, Brisbane, Queensland; 3Department of Nutrition
and Dietetics, Logan Hospital, Queensland; 4Department of Nutrition and Dietetics, Royal Brisbane and Women’s Hospital, Queensland; 5Department of Nutrition and Dietetics, Nambour Hospital, Queensland; 6Department of Nutrition and Dietetics, Ipswich Hospital, Queensland, Australia Aim: To evaluate the effectiveness of meal replacement regimens as part of usual care for weight
reduction in obese patients with chronic kidney disease (CKD). Background: Obesity management in CKD is recommended for modifying cardiovascular risk, disease progression and is frequently required for transplant list activation. Meal replacements have been shown to effectively induce weight loss however there Carnitine dehydrogenase is a paucity of data regarding the effectiveness or safety in CKD. Methods: This prospective observational study included a convenience sample of CKD patients under the care of dietitian for meal replacements. Prescription, client progress and outcomes were tracked using a standardised form. Factors associated with successful weight loss (>5%) were evaluated using t-test and chi-square. Results: Patients were recruited across five sites (n = 16) (December 2012 to January 2014). Mostly females (69%, n = 11) with CKD stage I–IV (69%, n = 11), 21% stage V (n = 5) and average BMI (43.8 ± 10.1 kg/m2). On average (range) participants were prescribed 56% (24–93%) and 94% (53–118%) of estimated energy and protein requirements, respectively. Average duration of intervention was 34 weeks (3–73) achieving weight change of −4.3% (+6.0%, −22%). Seven patients (44%) achieved >5% weight loss; they were more likely to have been referred for meal replacements by the team (86%, n = 6/7) and more frequently reviewed (1 review/24 ± 14days) compared with those who were unsuccessful (1 review/51 ± 31days, 22% n = 2/9 team-referred) (P < 0.05).
Related posts:
- Dienogest highly recommended that the turnaround time from the histological diagnosis of gastric cancer
- ENMD-2076 was defined as a report on the Common Criteria toxicity
- Results: Two hundred and five miRNAs were differentially expresse
- Methods: Male Sprague-Dawley rats were randomly allocated to 4 tr
- Surprisingly, an HIV diagnosis during pregnancy did not put women